Harvard Bioscience(US:HBIO)2025-11-06 13:00Financial Performance - Revenue for Q3 2025 was $20.6 million, at the high end of the $19-$21 million guidance range[7, 8] - Gross margin for Q3 2025 was 58.4%, exceeding the guidance range of 56%-58%[7, 8] - Adjusted EBITDA for Q3 2025 was $2.0 million, compared to $1.3 million in Q3 2024[7, 8] - Cash provided by operations was $6.8 million, up from ($0.3 million) in the same period last year[7] Regional Performance - APAC revenue decreased by 19.6% year-over-year, impacted by China tariffs[9] - EMEA revenue was relatively flat, down 0.6% year-over-year, influenced by macroeconomic instability[9] - Americas revenue decreased by 4.4% year-over-year, with a recovery in Pre-Clinical driven by NIH/ACA funding[9] Outlook and Strategy - The company is focused on refinancing or repaying the existing credit agreement in Q4 2025[7] - Q4 revenue is projected to range from $22.5 million to $24.5 million[17] - Q4 gross margin is expected to range from 58% to 60%[17]